MedTrace Logo

A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.

NCT05137067 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-03-21

No results posted yet for this study

Summary

This study will assess the effectiveness of a natural nutraceutical in treating the known side effects of chemotherapeutic agents in cancer patients.

Conditions

Interventions

DIETARY_SUPPLEMENT

Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)

Chemotherapeutic side effect elimination without adversely effecting the Chemotherapeutic agent drug.

DRUG

Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo

Placebo

DRUG

Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).

Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).

Sponsors & Collaborators

  • Optimal Health Research

    lead OTHER

Principal Investigators

  • EA Jeppsen, MD · Optimal Health Clinic

  • Steven Osguthorpe, ND · Optimal Health Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-20
Primary Completion
2022-10-18
Completion
2023-05-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05137067 on ClinicalTrials.gov